IGC Pharma Inc (IGC)
0.4163
-0.01
(-2.05%)
USD |
NYAM |
Jun 28, 16:00
0.4123
0.00 (0.00%)
After-Hours: 20:00
IGC Pharma Research and Development Expense (Annual): 3.773M for March 31, 2024
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.773M |
| March 31, 2023 | 3.461M |
| March 31, 2022 | 2.33M |
| March 31, 2021 | 0.929M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.011M |
| March 31, 2019 | 1.256M |
| March 31, 2018 | 0.137M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
0.929M
Minimum
2021
3.773M
Maximum
2024
2.301M
Average
2.33M
Median
2022
Research and Development Expense (Annual) Benchmarks
| CEL-SCI Corp | 22.47M |
| AIM ImmunoTech Inc | 10.94M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Protalix BioTherapeutics Inc | 17.09M |
| Palatin Technologies Inc | 22.63M |